A) Appendix 4. Meta-analysis of Common Indicators in Final Studies with the RevMan Software .

Study	Strategy	Validity Index	MD. 95% CI	p
Wilschut LH Vanrossom LG	FOBT, FIT 50ng/dl	CRC specifity	1.16[-96.10,98.42]	0.98
Wilschut LH Vanrossom LG	FOBT, FIT 50ng/dl	Advanced adenoma specifity	2.11[-95.57,99.79]	0.97
Wilschut LH Vanrossom LG Dancourt V	FOBT, FIT 50ng/dl	CRC PPV	0.71[-5.25,6.66]	0.82
Wilschut LH Vanrossom LG Dancourt V	FOBT, FIT 50ng/dl	Advanced adenoma PPV	-5.48[-32.12,21.15]	0.69
Vanrossom LG Dancourt V	FOBT, FIT 50ng/dl	Non-Advanced adenoma PPV	-1.32[-17.32,14.69]	0.87
Hughes k Vanrossom LG	FOBT,FIT 50ng/dl	Participation rate	-9.74[-50.92,31.45]	0.64
Hughes k Vanrossom LG Wilschut LH Dancourt V	FOBT, FIT 50ng/dl	Positivity rate	-4.06[-7.89,-0.24]	0.04
Vanrossom LG Wilschut LH	FOBT, FIT 50ng/dl	CRC detection rate	-0.99[-2.08,0.09]	0.07
Vanrossom LG Wilschut LH	FOBT, FIT 50ng/dl Advanced adenoma	-1.00[-2.39,0.39]	0.16
Brenner H Wilschut LH	FOBT, FIT 100ng/dl	CRC specifity	1.15[-95.24, 96.55]	0.99
Brenner H Wilschut LH	FOBT, FIT 100ng/dl	Advanced adenoma specifity	-0.67[-97.90, 96.55]	0.99
Brenner H Wilschut LH	FOBT, FIT 100ng/dl	CRC PPV	-16.77[-61.12, 27.58]	0.46
Brenner H Wilschut LH	FOBT, FIT 100ng/dl	Advanced adenoma PPV	-24.53[-67.43, 18.37]	0.26